Keytruda And Small Cell Lung Cancer

Findings of the phase 1b keynote 028 trial were published in the journal of clinical oncology.

Keytruda and small cell lung cancer.

Keytruda is a prescription medicine used to treat a kind of lung cancer called non small cell lung cancer nsclc. The immunotherapy agent keytruda pembrolizumab had an overall response rate orr of 33 percent in a recent trial including patients with extensive stage small cell lung cancer sclc. Keytruda may be used with the chemotherapy medicines pemetrexed and a platinum as your first treatment when your lung cancer has spread advanced nsclc and is a type called nonsquamous and your tumor does not have an abnormal egfr or alk gene. Merck co s keytruda may be the star in non small cell lung cancer but a combo of it and chemo just failed to significantly outdo chemo alone at prolonging patients lives in small cell.

Keytruda pembrolizumab is used to treat advanced melanoma non small cell lung cancer small cell lung cancer head and neck squamous cell carcinoma classical hodgkin lymphoma primary mediastinal large b cell lymphoma urothelial carcinoma microsatellite instability high cancer gastric cancer esophageal cancer cervical cancer hepatocellular carcinoma merkel cell carcinoma renal cell.